-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56

Benzinga·08/21/2026 09:54:38
Listen to the news
Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.